Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar 2:3:15.
doi: 10.3389/fpsyt.2012.00015. eCollection 2012.

Metal chaperones: a holistic approach to the treatment of Alzheimer's disease

Paul Anthony Adlard  1 , Ashley Ian Bush
Affiliations

Metal chaperones: a holistic approach to the treatment of Alzheimer's disease

Paul Anthony Adlard et al. Front Psychiatry. .

Abstract

As evidence for the role of metal ion dysregulation in the pathogenesis of multiple CNS disorders grows, it has become important to more precisely identify and differentiate the biological effects of various pharmacological modulators of metal ion homeostasis. This is particularly evident in disorders such as Alzheimer's disease (AD), where the use of metal chaperones (that transport metals), as opposed to chelators (which exclude metals from biological interactions), may prove to be the first truly disease modifying approach for this condition. The purpose of this mini-review is to highlight the emerging notion that metal chaperones, such as PBT2 (Prana Biotechnology), modulate a variety of critical pathways affecting key aspects of the AD cascade to provide a more "holistic" approach to the treatment of this disease.

Keywords: Alzheimer’s disease; PBT2; cohaperone; metal; therapeutic.

PubMed Disclaimer

References

    1. Adlard P. A., Bica L., White A. R., Nurjono M., Filiz G., Crouch P. J., Donnelly P. S., Cappai R., Finkelstein D. I., Bush A. I. (2011). Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer’s disease. PLoS ONE 6, e17669.10.1371/journal.pone.0017669 - DOI - PMC - PubMed
    1. Adlard P. A., Bush A. I. (2006). Metals and Alzheimer’s disease. J. Alzheimers Dis. 10, 145–163 - PubMed
    1. Adlard P. A., Cherny R. A., Finkelstein D. I., Gautier E., Robb E., Cortes M., Volitakis I., Liu X., Smith J. P., Perez K., Laughton K., Li Q. X., Charman S. A., Nicolazzo J. A., Wilkins S., Deleva K., Lynch T., Kok G., Ritchie C. W., Tanzi R. E., Cappai R., Masters C. L., Barnham K. J., Bush A. I. (2008). Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59, 43–5510.1016/j.neuron.2008.06.018 - DOI - PubMed
    1. Adlard P. A., James S. A., Bush A. I., Masters C. L. (2009). Beta-amyloid as a molecular therapeutic target in Alzheimer’s disease. Drugs Today 45, 293–30410.1358/dot.2009.045.004.1353853 - DOI - PubMed
    1. Adlard P. A., Parncutt J. M., Finkelstein D. I., Bush A. I. (2010). Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer’s disease? J. Neurosci. 30, 1631–163610.1523/JNEUROSCI.5255-09.2010 - DOI - PMC - PubMed